Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Actinic keratosis - review for clinical practice

Full text
Author(s):
de Oliveira, Erika C. V. [1] ; da Motta, Valeria R. V. [1] ; Pantoja, Paola C. [2] ; Ilha, Carolina S. de O. [3] ; Magalhaes, Renata F. [4] ; Galadari, Hassan [5] ; Leonardi, Gislaine R. [2]
Total Authors: 7
Affiliation:
[1] Univ Estadual Campinas, UNICAMP Brazil, Med Sci Fac, Med Clin, Post Grad Program, Campinas, SP - Brazil
[2] Univ Estadual Campinas, UNICAMP Brazil, Fac Pharmaceut Sci, Campinas, SP - Brazil
[3] Univ Estadual Campinas, UNICAMP Brazil, Med Sci Fac, Dermatol Med Residence Program, Campinas, SP - Brazil
[4] Univ Estadual Campinas, UNICAMP Brazil, Med Sci Fac, Dermatol Dept, Campinas, SP - Brazil
[5] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Dermatol, Al Ain - U Arab Emirates
Total Affiliations: 5
Document type: Review article
Source: INTERNATIONAL JOURNAL OF DERMATOLOGY; v. 58, n. 4, p. 400-407, APR 2019.
Web of Science Citations: 6
Abstract

Actinic keratosis (AK) is a lesion that arises as a result of excessive exposure to solar radiation and appearing predominantly on Fitzpatrick phototype I and II skin. Given that some AKs evolve into squamous cell carcinoma, these lesions are considered premalignant in nature, occurring mostly in elderly men and immunosuppressed individuals chronically exposed to ultraviolet (UV) radiation. There are several mechanisms for the formation of AKs; among them are oxidative stress, immunosuppression, inflammation, altered proliferation and dysregulation of cell growth, impaired apoptosis, mutagenesis, and human papillomavirus (HPV). Through the understanding of these mechanisms, several treatments have emerged. Among the options for AK treatment, the most commonly used include 5-fluorouracil (5-FU), cryotherapy, diclofenac, photodynamic therapy (PDT), imiquimod (IQ), retinoids, and ingenol mebutate (IM). There have been recent advances in the treatment options that have seen the emergent use of newer agents such as resiquimod, betulinic acid, piroxicam, and dobesilate. The combination between therapies has presented relevant results with intention to reduce duration of therapy and side effects. All AK cases must be treated because of their propensity to transform into malignancy and further complicate treatment. In addition to medical or surgical care, education about sun exposure prevention remains the best and most cost-effective method for AK prevention. The objective of this article is to conduct a literature review of the clinical presentation of AK including advances in treatment options available. (AU)

FAPESP's process: 15/02129-6 - DEVELOPMENT AND EVALUATION OF RETINOIC ACID DRUG DELIVERY SYSTEMS PROVIDED BY MICROPARTICLES OF K-CARRAGEENAN IN EMULSIFIED SYSTEMS CONSTITUTED, OR NOT, OF LIQUID CRISTALLINE STRUCTURES
Grantee:Gislaine Ricci Leonardi
Support type: Regular Research Grants